Phillip James Consulting’s AbbVie ABBV Stock Holding History

Phillip James Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.6K	Hold	185	–	–	0.03%	101
2026 Q1	$40K	Buy	185 +17	+10%	+$3.77K	0.03%	124
2025 Q4	$36K	Buy	+168	New	+$38.3K	0.64%	34

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Phillip James Consulting's ABBV Position: Q2 2026 in Review

Phillip James Consulting held its AbbVie (ABBV) position steady in Q2 2026 at 185 shares worth $46.6K. The position accounts for 0.03% of the portfolio, ranked #101.

Phillip James Consulting first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Phillip James Consulting held 185 shares of AbbVie worth $46.6K as of Q2 2026.
Phillip James Consulting left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.03% of Phillip James Consulting's portfolio in Q2 2026, its #101 holding.
Phillip James Consulting first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Phillip James Consulting's 13F filing for Q2 2026, filed 28 Jul 2026.